🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Yee Chao

Fu Jen Catholic University

ORCID: 0000-0001-5578-340X

Also affiliated with Soma Central Hospital

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 5 papers. Top paper: “Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma”.

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Annals of Oncology(2024)10.1016/j.annonc.2024.02.005
N/A
0.868DataRank · unranked
326 citations

S.L. Chan, R.K. Kelley, G. Lau, M. Kudo, W. Sukeepaisarnjaroen +198 more

A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer

Cancer Chemotherapy and Pharmacology(2013)10.1007/s00280-013-2239-1
N/A
0.538DataRank · unranked
35 citations

Chen-Yi Wu, Jack P. Wang, Rheun-Chuan Lee, Wei-Ping Lee, Chung-Pin Li +1 more

Data from A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

(2023)10.1158/1078-0432.c.6526233.v1
N/A
0DataRank · unranked
0 citations

Riccardo Lencioni, Wattana Sukeepaisarnjaroen, Yee Chao, Chia‐Jui Yen, Wirote Lausoontornsiri +13 more

Phase I–II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04714-z
N/A
0DataRank · unranked
2 citations

Axel Grothey, Darren Sigal, Heinz-Josef Lenz, Howard S. Höchster, Yee Chao +5 more

Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-Line Immunotherapy: A Phase II Clinical Study

International Journal of Radiation Oncology*Biology*Physics(2025)10.1016/j.ijrobp.2025.06.1219
N/A
0DataRank · unranked
0 citations

Yee Chao, Lingling Wang, Qiufan Zheng, Y. Zhang, Y. Hu +4 more